Literature DB >> 33883221

Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Daniel P Leaman1, Armando Stano1, Yajing Chen1, Lei Zhang1, Michael B Zwick1.   

Abstract

A major goal of HIV vaccine design is to elicit broadly neutralizing antibodies (bNAbs). Such bNAbs target HIV's trimeric, membrane-embedded envelope glycoprotein spikes (mEnv). Soluble Env (sEnv) trimers have been used as vaccines, but engineering sEnvs for stability, multivalency, and desired antigenicity is problematic and deletes key neutralizing epitopes on glycoprotein 41 (gp41) while creating neoepitopes that elicit unwanted antibodies. Meanwhile, multivalent mEnv vaccines are challenging to develop due to trimer instability and low mEnv copy number amid other extraneous proteins on virus-like particles. Here, we describe a multivalent mEnv vaccine platform that does not require protein engineering or extraneous proteins. mEnv trimers were fixed, purified, and combined with naked liposomes in mild detergent. On removal of detergent, mEnv spikes were observed embedded in liposome particles (mean diameter, 133 nm) in correct orientation. These particles were recognized by HIV bNAbs and not non-NAbs and are designated mEnv liposomes (MELs). Following a sequential immunization scheme in rabbits, MELs elicited antibodies that neutralized tier 2 HIV isolates. Analysis of serum antibody specificities, including those to epitopes involving a missing conserved N-glycosylation site at position 197 near the CD4 binding site on two of the immunogens, provides clues on how NAb responses can be improved with modified immunogens. In sum, MELs are a biochemically defined platform that enables rational immunization strategies to elicit HIV bNAbs using multimerized mEnv. IMPORTANCE A vaccine that induced broadly neutralizing antibodies against HIV would likely end the AIDS pandemic. Such antibodies target membrane-embedded envelope glycoprotein spikes (mEnv) that HIV uses to enter cells. Due to HIV Env's low expression and instability, soluble stabilized Env trimers have been used as vaccine candidates, but these have an altered base that disrupts targets of HIV broadly neutralizing antibodies that bind near the membrane and are not available for all HIV isolates. Here, we describe membrane Env liposomes (MELs) that display a multivalent array of stable mEnvs on liposome particles. MELs showed the expected antibody recognition properties, including targeting parts of mEnv missing on soluble Envs. Immunization with MELs elicited antibodies that neutralized diverse HIV isolates. The MEL platform facilitates vaccine development with potentially any HIV Env at high valency, and a similar approach may be useful for eliciting antibodies to membrane-embedded targets of therapeutic interest.

Entities:  

Keywords:  HIV; envelope; gp120; gp41; immunogen; liposome; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33883221      PMCID: PMC8316072          DOI: 10.1128/JVI.00005-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.

Authors:  Javier Guenaga; Viktoriya Dubrovskaya; Natalia de Val; Shailendra K Sharma; Barbara Carrette; Andrew B Ward; Richard T Wyatt
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

2.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

4.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

5.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Authors:  Josh D Nelson; Heather Kinkead; Florence M Brunel; Dan Leaman; Richard Jensen; John M Louis; Toshiaki Maruyama; Carole A Bewley; Katherine Bowdish; G Marius Clore; Philip E Dawson; Shana Frederickson; Rose G Mage; Douglas D Richman; Dennis R Burton; Michael B Zwick
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

Review 6.  Multiple roles for HIV broadly neutralizing antibodies.

Authors:  Barton F Haynes; Dennis R Burton; John R Mascola
Journal:  Sci Transl Med       Date:  2019-10-30       Impact factor: 17.956

7.  Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.

Authors:  Wilton B Williams; Jinsong Zhang; Chuancang Jiang; Nathan I Nicely; Daniela Fera; Kan Luo; M Anthony Moody; Hua-Xin Liao; S Munir Alam; Thomas B Kepler; Akshaya Ramesh; Kevin Wiehe; James A Holland; Todd Bradley; Nathan Vandergrift; Kevin O Saunders; Robert Parks; Andrew Foulger; Shi-Mao Xia; Mattia Bonsignori; David C Montefiori; Mark Louder; Amanda Eaton; Sampa Santra; Richard Scearce; Laura Sutherland; Amanda Newman; Hilary Bouton-Verville; Cindy Bowman; Howard Bomze; Feng Gao; Dawn J Marshall; John F Whitesides; Xiaoyan Nie; Garnett Kelsoe; Steven G Reed; Christopher B Fox; Kim Clary; Marguerite Koutsoukos; David Franco; John R Mascola; Stephen C Harrison; Barton F Haynes; Laurent Verkoczy
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 17.694

8.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.

Authors:  Gabriel Ozorowski; Albert Cupo; Michael Golabek; Michelle LoPiccolo; Thomas A Ketas; Matt Cavallary; Christopher A Cottrell; P J Klasse; Andrew B Ward; John P Moore
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

9.  HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies.

Authors:  Kimmo Rantalainen; Zachary T Berndsen; Aleksandar Antanasijevic; Torben Schiffner; Xi Zhang; Wen-Hsin Lee; Jonathan L Torres; Lei Zhang; Adriana Irimia; Jeffrey Copps; Kenneth H Zhou; Young D Kwon; William H Law; Chaim A Schramm; Raffaello Verardi; Shelly J Krebs; Peter D Kwong; Nicole A Doria-Rose; Ian A Wilson; Michael B Zwick; John R Yates; William R Schief; Andrew B Ward
Journal:  Cell Rep       Date:  2020-04-28       Impact factor: 9.423

10.  An MPER antibody neutralizes HIV-1 using germline features shared among donors.

Authors:  Lei Zhang; Adriana Irimia; Lingling He; Elise Landais; Kimmo Rantalainen; Daniel P Leaman; Thomas Vollbrecht; Armando Stano; Daniel I Sands; Arthur S Kim; Pascal Poignard; Dennis R Burton; Ben Murrell; Andrew B Ward; Jiang Zhu; Ian A Wilson; Michael B Zwick
Journal:  Nat Commun       Date:  2019-11-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.